Publications by authors named "Gregory C Janis"

Background: Toxicity from antimuscarinic agents precipitates a constellation of signs and symptoms; two of the most significant are agitation and delirium. Benzodiazepines are commonly used for treatment; physostigmine is also effective but is underutilized due to concerns for safety and short duration of action. The objective of this study was to compare lorazepam to physostigmine for the treatment of antimuscarinic delirium and agitation.

View Article and Find Full Text PDF
Article Synopsis
  • The study addresses the issue of urine drug screens mistakenly identifying CBD users as marijuana users due to trace amounts of THC in some CBD products.
  • A new assay was developed to differentiate between marijuana use and CBD use contaminated with THC by measuring specific urinary metabolites.
  • Results showed that a significant portion of samples from CBD users had higher levels of CBD metabolites compared to THC metabolites, supporting the effectiveness of the assay in correctly classifying users.
View Article and Find Full Text PDF

Marijuana use has been postulated to modulate opioid use, dependence and withdrawal. Broad target drug testing results provide a unique perspective to identify any potential interaction between marijuana use and opioid use. Using a dataset of approximately 800,000 urine drug test results collected from pain management patients of a time from of multiple years, creatinine corrected opioid levels were evaluated to determine if the presence of the primary marijuana marker 11-nor-carboxy-tetrahydrocannabinol (THC-COOH) was associated with statistical differences in excreted opioid concentrations.

View Article and Find Full Text PDF

Meconium, the first stool of a newborn, can be analyzed to identify prenatal exposure to drugs of abuse. Meconium accumulates in a fetus during the second and third trimesters of pregnancy providing a wide window of exposure. Identification of in utero drug exposure is essential for the diagnosis and treatment of infants for dependency/withdrawal caused from the exposure.

View Article and Find Full Text PDF

The analysis of synthetic cannabinoid compounds in a urine sample is currently one of the more complex tasks facing toxicologists. The list of prevalent compounds in circulation at any given time is constantly in flux, changing at a rapid rate to avoid legal control and to a lesser extent to avoid detection. Even with knowledge of the chemical entities, their detection in urine is complicated by the fact that they are present exclusively as both phase I metabolites and phase II conjugates.

View Article and Find Full Text PDF

Background: Since 2013, an unprecedented surge in fentanyl overdose deaths has been caused by heroin laced with illicitly produced fentanyl and/or fentanyl analogs (FAs) sold as heroin. The US Drug Enforcement Agency's National Forensic Laboratory Information System reported a >300% increase in fentanyl encounters from 4697 in 2014 to 14440 in 2015. In 2015, the CDC reported 9580 deaths caused by synthetic opioids, primarily fentanyl, a 72% increase from 2014.

View Article and Find Full Text PDF
Article Synopsis
  • The rise of illicit opioids, often disguised as prescription medications, poses serious public health risks due to unknown potencies and higher overdose potential, especially with drugs like fentanyl.
  • Methods were developed to accurately identify and measure fentanyl and 18 designer opioids in urine samples, specifically targeting those from pain management patients.
  • In a study of pain management patients, 25% of those with heroin in their system tested positive for designer opioids, while less than 1% tested positive in random pain samples, highlighting a significant correlation between heroin use and designer opioid exposure.
View Article and Find Full Text PDF

A wide range of concentrations are frequently observed when measuring drugs of abuse in urine toxicology samples; this is especially true for amphetamine and methamphetamine. Routine liquid chromatography-tandem mass spectrometry confirmatory methods commonly anchored at a 50 ng/mL lower limit of quantitation can span approximately a 100-fold concentration range before regions of non-linearity are reached deteriorating accurate quantitation and qualitative assessments. In our experience, approximately a quarter of amphetamine and methamphetamine positive samples are above a 5,000 ng/mL upper limit of quantitation and thus require reanalysis with dilution for accurate quantitative and acceptable qualitative results.

View Article and Find Full Text PDF

The illicit drug market has seen an increase in designer opioids, including fentanyl and methadone analogs, and other structurally unrelated opioid agonists. The designer opioid, furanyl fentanyl, is one of many fentanyl analogs clandestinely synthesized for recreational use and contributing to the fentanyl and opioid crisis. A method has been developed and validated for the analysis of furanyl fentanyl and furanyl norfentanyl in urine specimens from pain management programs.

View Article and Find Full Text PDF
Article Synopsis
  • Urine drug testing is critical in various fields, which has led some individuals to attempt to cheat the process using synthetic urine.
  • Current safeguards like measuring temperature and analyzing creatinine, specific gravity, and pH are standard to ensure sample validity.
  • The research developed new methods to differentiate real samples from synthetic ones by identifying unique compounds in synthetic urine and evaluating additional validity markers.
View Article and Find Full Text PDF

Context: The opioid epidemic has included use of traditional drugs and recently newer synthetics. It is critically important to recognize and identify these new drugs both clinically and through appropriately designed toxicology testing. There is little available information on a synthetic gaining popularity, U-47700.

View Article and Find Full Text PDF

Gas chromatography/mass spectrometry (GC/MS) is a primary tool used to identify compounds in complex samples. Both mass spectra and GC retention times are matched to those of standards; however, it is often impractical to have standards on hand for every compound of interest, so we must rely on shared databases of MS data and GC retention information. Unfortunately, retention databases (e.

View Article and Find Full Text PDF

Introduction: 2C designer drugs have been in use since the 1970s, but new drugs continue to develop from substitutions to the base phenethylamine structure. This creates new clinical profiles and difficulty with laboratory confirmation. 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) is a relatively new 2C drug that is more potent than structural 2C analogs; exposure reports are rare.

View Article and Find Full Text PDF

The leaves of the South Asian plant kratom are described as having stimulating effects at low doses, and opiate-like analgesic and euphoric effects at high doses. A long history of use and abuse has led to the classification of kratom as a controlled substance in its native Thailand and other South Asian countries. However, kratom is not controlled in the United States, and the ready availability of kratom has led to its emergence as an herbal drug of abuse.

View Article and Find Full Text PDF

A method for the analysis of the basic antiepileptic compounds felbamate, lamotrigine, carbamazepine, carbamazepine-10,11-epoxide, gabapentin, pregabalin, levetiracetam, and oxcarbazepine monohydroxy derivative (oxcarb MHD) in human plasma is described. This protocol incorporates a simplified sample preparation step followed by quantitative high performance chromatography-tandem mass spectrometry detection of commonly prescribed and monitored anticonvulsant drugs. Since polytherapy is common in epilepsy patients, use of a multiconstituent assay can improve laboratory efficiency and reduce required analytical time.

View Article and Find Full Text PDF

Background: Patients with iron-deficiency anemia benefit from intravenous iron therapies. Development of these pharmaceutical agents requires pharmacokinetic studies monitoring levels of both the administered agent and transferrin-bound iron (TBI). Successful pharmacokinetic methods must discriminate iron species.

View Article and Find Full Text PDF